Mustang Bio, Inc. announced that its IL13Ra2-targeted CAR T-cell therapy, MB-101, received Orphan Drug Designation from the FDA for treating recurrent diffuse and anaplastic astrocytomas and ...
For more information, please click here. Mustang is collaborating with City of Hope on several chimeric antigen receptor T cell clinical trials, including MB‐101 (IL13Rα2‐targeted CAR T cells) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results